Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring
Authors:
Abstract
Crohn's disease is characterised by recurrent and/or chronic inflammation of the gastrointestinal tract leading to cumulative intestinal tissue damage. Treatment tailoring to try to prevent this tissue damage as well as achieve optimal benefit/risk ratio over the whole disease course is becoming an important aspect of Crohn's disease management. For decades, clinical symptoms have been the main trigger for diagnostic procedures and treatment strategy adaptations. However, the correlation between symptoms and intestinal lesions is only weak. Furthermore, preliminary evidence suggests that a state of remission beyond the simple control of clinical symptoms, and including mucosal healing, may be associated with better disease outcome. Therefore monitoring the disease through the use of endoscopy and cross-sectional imaging is proposed. However, the degree of mucosal or bowel wall healing that needs to be reached to improve disease outcome has not been appropriately studied. Furthermore, owing to their invasive nature and cost, endoscopy and cross-sectional imaging are not optimal tools for the patients or the payers. The use of biomarkers as surrogate markers of intestinal and systemic inflammation might help. Two biomarkers have been most broadly assessed in Crohn's disease: C-reactive protein and faecal calprotectin. These markers correlate significantly with endoscopic lesions, with the risk of relapse and with response to therapy. They could be used to help make decisions about diagnostic procedures and treatment. In particular, with the use of appropriate threshold values, they could determine the need for endoscopic or medical imaging procedures to confirm the disease activity state.Keywords
This publication has 69 references indexed in Scilit:
- Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's diseaseGut, 2011
- Gastroenterology Review and Perspective: The Role of Cross-Sectional Imaging in Evaluating Bowel Damage in Crohn DiseaseAmerican Journal of Roentgenology, 2011
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective studyEuropean Journal of Gastroenterology & Hepatology, 2010
- Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatmentScandinavian Journal of Gastroenterology, 2009
- Abdominal Sonographic Changes After Antibody to Tumor Necrosis Factor (Anti-TNF) Alpha Therapy in Crohn’s DiseaseDigestive Diseases and Sciences, 2009
- Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel diseaseWorld Journal of Gastroenterology, 2008
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive proteinGut, 2006